

SHEET 1 of 5

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28341/6216.NDV2

Serial No.

10/657,399

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Fisher et al.

Filing Date

September 8, 2003

Group

Not yet assigned

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
MM	A1	5,283,173	02-01-94	Fields, <i>et al.</i>			
	A2	5,376,742	12-27-94	Krause			
	A3	5,457,189	10-10-95	Crooke, <i>et al.</i>			
	A4	5,547,846	08-20-96	Bartsch, <i>et al.</i>			
	A5	5,576,206	11-19-96	Schlegel			
	A6	5,625,031	04-29-97	Webster, <i>et al.</i>			
	A7	5,629,161	05-13-97	Müller, <i>et al.</i>			
	A8	5,681,944	10-28-97	Crooke, <i>et al.</i>			
	A9	5,736,318	04-07-98	Münger, <i>et al.</i>			
	A10	5,811,232	09-22-98	Crooke, <i>et al.</i>			

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
MM	B1	95/20652	08-03-95	WO				
	B2	98/13502	04-02-98	WO				
	B3	0 666 270 A2	08-09-95	EPO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

MM	C1	Antinore, <i>et al.</i> , "The human papillomavirus type 16 E7 gene product interacts with and <i>trans</i> -activates the AP1 family of transcription factors," <i>EMBO. J.</i> , 15:1950-60 (1996)
	C2	Arroyo, <i>et al.</i> , "Association of the Human Papillomavirus Type 16 E7 Protein with the S-Phase-Specific E2F-Cyclin A Complex," <i>Mol. Cel. Biol.</i> 13:6537-6456 (1993)
	C3	Banks, <i>et al.</i> , "Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells," <i>Oncogene</i> 5:1383-1389 (1990)


EXAMINER

Moller

DATE CONSIDERED

9-28-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SHEET 2 of 5

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

28341/6216.NDV2

Serial No.

10/657,399

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant

Fisher et al.

Filing Date

September 8, 2003

Group

Not yet assigned

mm	C4	Cane, <i>et al.</i> , "Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations," <i>Science</i> 282:63-68 (1998)
	C5	Chen, <i>et al.</i> , "Cyclin-Binding Motifs Are Essential for the Function of p21 <sup>CIP1</sup> ," <i>Mol. Cell. Biol.</i> 16:4673-82 (1996)
	C6	Cheng, <i>et al.</i> , "Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes," <i>Genes &amp; Dev.</i> 9:2335-49 (1995)
	C7	Chow, <i>et al.</i> , "Papillomavirus DNA Replication," <i>Intervirology</i> 37:150-8 (1994)
	C8	Ciccolini, <i>et al.</i> , "Functional studies of E7 proteins from different HPV types," <i>Oncogene</i> 9:2633-8 (1994)
	C9	Colas, <i>et al.</i> , "The impact of two-hybrid and related methods on biotechnology," <i>TIBTECH</i> 16:355-363 (1998)
	C10	Connell-Crowley, <i>et al.</i> , "Phosphorylation Independent Activation of Human Cyclin-Dependent Kinase 2 by Cyclin A In Vitro," <i>Mol. Biol. Cell</i> 4:79-92 (1993)
	C11	Davies, <i>et al.</i> , "Human Papillomavirus Type 16 E7 Associates with a Histone H1 Kinase and with p107 through Sequences Necessary for Transformation," <i>J. Virol.</i> , 67:2521-8 (1993)
	C12	Draetta, <i>et al.</i> , "cdc2 Protein Kinase is Complexed with Both Cyclin A and B: Evidence for Proteolytic Inactivation of MPF," <i>Cell</i> 56:829-838 (1989)
	C13	Dyson, <i>et al.</i> , "Homologous Sequences in Adenovirus E1A and Human Papillomavirus E7 Proteins Mediate Interaction with the Same Set of Cellular Proteins," <i>J. Virol.</i> 66:6893-6902 (1992)
	C14	Dyson, <i>et al.</i> , "The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene Product," <i>Science</i> 243:934-7 (1989)
	C15	Fields, <i>et al.</i> , "A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340:245-246 (1989)
	C16	Fields, "The Two-Hybrid System to Detect Protein-Protein Interactions," <i>Methods: A Companion to Methods in Enzymology</i> 5:116-124 (1993)
	C17	Funk, <i>et al.</i> , "Inhibiting CDK inhibitors: new lessons from DNA tumor viruses," Elsevier Science Ltd. 337-341 (1998)
	C18	Funk, <i>et al.</i> , "Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein," <i>Genes &amp; Dev.</i> 11:2090-100 (1997)
u	C19	Galloway, <i>et al.</i> , "The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia," <i>Semin. Cancer Biol.</i> 7:309-15 (1996)

EXAMINER

moxley

DATE CONSIDERED

9-28-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28341/6216.NDV2	Serial No. 10/657,399
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant Fisher et al.	
		Filing Date September 8, 2003	Group Not yet assigned

MM	C20	Harper, <i>et al.</i> , "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," <i>Cell</i> 75:805-816 (1993)
	C21	Houston, <i>et al.</i> , "The chemical-biological interface: developments in automated and miniaturised screening technology," <i>Curr. Opin. Biotechnol.</i> 8:734-740 (1997)
	C22	Jayawickreme, <i>et al.</i> , "Gene expression systems in the development of high-throughput screens," <i>Curr. Opin. Biotechnol.</i> 8:629-634 (1997)
	C23	Jones, <i>et al.</i> , "The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2," <i>Genes &amp; Dev.</i> 11:2101-11 (1997)
	C24	Jones, <i>et al.</i> , "Interactions of the human papillomavirus E7 protein with cell cycle regulators," <i>Cancer Biology</i> 7:327-337 (1996)
	C25	Koonin, "A common set of conserved motifs in a vast variety of putative nucleic acid-dependent ATPases including MCM proteins involved in the initiation of eukaryotic DNA replication," <i>Nucl. Acids Res.</i> 21:2541-7 (1993)
	C26	Ma, <i>et al.</i> , "Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication," <i>Proc. Natl. Acad. Sci. (USA)</i> 96:382-7 (1999)
	C27	Massimi, <i>et al.</i> , "HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation," <i>Oncogene</i> 12:2325-30 (1996)
	C28	McIntyre, <i>et al.</i> , "Human Papillomavirus E7 Oncoproteins Bind a Single Form of Cyclin E in a Complex with cdk2 and p107," <i>Virology</i> 215:73-82 (1996)
	C29	Morgan, "CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors," <i>Ann. Rev. Cell Dev. Biol.</i> 13:261-291 (1997)
	C30	Mulligan, <i>et al.</i> , "The retinoblastoma gene family: cousins with overlapping interests," <i>Trends Genet</i> 14:223-9 (1988)
	C31	Myers, "Will combinatorial chemistry deliver real medicines?" <i>Curr. Opin. Biotechnol.</i> 8:701-707 (1997)
	C32	Pei, <i>et al.</i> , "HPV-16 E7 protein bypasses keratinocyte growth inhibition by serum and calcium," <i>Carcinogenesis</i> 19:1481-6 (1998)
	C33	Phelps, <i>et al.</i> , "Structure-Function Analysis of the Human Papillomavirus Type 16 E7 Oncoprotein," <i>J. of Virol.</i> 66:2418-2427 (1992)
	C34	Pietenpol, <i>et al.</i> , "TGF- $\alpha$ 1 Inhibition of c-myc Transcription and Growth in Keratinocytes Is Abrogated by Viral Transforming Proteins with pRB Binding Domains," <i>Cell</i> 61:777-85 (1990)
✓	C35	Pines, <i>et al.</i> , "Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B," <i>Nature</i> 346:760-763 (1990)


EXAMINER <i>modu</i>	DATE CONSIDERED 9-28-05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28341/6216.NDV2	Serial No. 10/657,399
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant Fisher et al.	
		Filing Date September 8, 2003	Group Not yet assigned

MM	C36	Polyak, <i>et al.</i> , "Cloning of p27 <sup>Kip1</sup> , a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals," <i>Cell</i> 78:59-66 (1994)
	C37	Remington's Pharmaceutical Sciences, 18 <sup>th</sup> Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712
	C38	Ruesch, <i>et al.</i> , "Human Papillomavirus Oncoproteins Alter Differentiation-Dependent Cell Cycle Exit on suspension in Semisolid Medium," <i>Virol.</i> 250:19-29 (1998)
	C39	Scheffner, <i>et al.</i> , "The E6 Oncoprotein Encoded by Human Papillomavirus Types 16 and 18 Promotes the Degradation of p53," <i>Cell</i> 63:1129-36 (1990)
	C40	Seedorf, <i>et al.</i> , "Human Papillomavirus Type 16 DNA Sequences," <i>Virol.</i> 145:181-185 (1985)
	C41	Sverdrup, <i>et al.</i> , "Replication of Human Papillomavirus (HPV) DNAs Supported by the HPV Type 18 E1 and E2 Proteins," <i>J. Virol.</i> 68:505-509 (1994)
	C42	Tommasino, <i>et al.</i> , "HPV16 E7 protein associates with the protein kinase p33 <sup>CDK2</sup> and cyclin A," <i>Oncogene</i> 8:195-202 (1993)
	C43	Toyoshima, <i>et al.</i> , "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," <i>Cell</i> 78:67-74 (1994)
	C44	Wu, <i>et al.</i> , "The Human Papillomavirus E7 Oncoprotein and the Cellular Transcription Factor E2F Bind to Separate Sites on the Retinoblastoma Tumor Suppressor Protein," <i>J. Virol.</i> 67:2402-7 (1993)
	C45	Zerfass, <i>et al.</i> , "Inactivation of the cdk inhibitor p27 <sup>KIP1</sup> by the human papillomavirus type 16 E7 oncoprotein," <i>Oncogene</i> 13:2323-30 (1996)
	C46	zur Hausen, "Papillomavirus infections — a major cause of human cancers," <i>Biochim. Biophys. Acta</i> 1288:F55-78 (1996)
	C47	Desai, <i>et al.</i> , "Activation of Human Cyclin-Dependent Kinases In Vitro," <i>Mol. Biol. Cell.</i> 3:571-582 (1992)
	C47	Desai, <i>et al.</i> , "Activation of Human Cyclin-Dependent Kinases In Vitro," <i>Mol. Biol. Cell.</i> 3:571-582 (1992)
	C47	Desai, <i>et al.</i> , "Activation of Human Cyclin-Dependent Kinases In Vitro," <i>Mol. Biol. Cell.</i> 3:571-582 (1992)
	C48	Roberts, "Evolving Ideas about Cyclins," <i>Cell</i> 98:129-132 (1999)
	C49	Ben-Bassat, <i>et al.</i> , "Inhibitors of Epidermal Growth Factor Receptor Kinase and of Cyclin-dependent Kinase 2 Activation Induce Growth Arrest, Differentiation, and Cancer Research 57(17):3741-3750 (1997)
✓	C50	Colas, <i>et al.</i> , "Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2," <i>Nature</i> 380:548-550 (1996)

EXAMINER Mofley	DATE CONSIDERED 9-28-05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28341/6216.NDV2	Serial No. 10/657,399
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		Applicant Fisher et al.	
		Filing Date September 8, 2003	Group Not yet assigned

	C51	Funk, <i>et al.</i> , "Inhibitor of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein," <i>Genes &amp; Devel.</i> 11:2090-2100 (1997)
	C52	International Search Report from PCT/US00/23487.

EXAMINER <i>molen</i>	DATE CONSIDERED <i>9-28-05</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	